Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Ning Ma, Lei Zhang, Wufang Zhang, Yingying He, Chong Ye & Xin Li. (2023) Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review. Neuropsychiatric Disease and Treatment 19, pages 1987-2006.
Read now
Read now
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz, Edward Kim, Wilson Tan, Bernardo Soares & Christoph U Correll. (2019) Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1365-1379.
Read now
Read now
Tianmei Si, Jianmin Zhuo, Yu Feng, Huafei Lu, Di Hong & Lili Zhang. (2019) Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1685-1694.
Read now
Read now
Nan Li, Jian Min Zhuo, Ibrahim Turkoz, Maju Mathews, Yu Feng & Wilson Tan. (2019) A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics. Expert Opinion on Pharmacotherapy 20:16, pages 2033-2039.
Read now
Read now
Maju Mathews, Isaac Nuamah, Adam J Savitz, David W Hough, Dean Najarian, Edward Kim & Srihari Gopal. (2018) Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. Neuropsychiatric Disease and Treatment 14, pages 2807-2816.
Read now
Read now
Huafang Li, Yan Li, Yu Feng, Jianmin Zhuo, Ibrahim Turkoz, Maju Mathews & Wilson Tan. (2018) Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study. Neuropsychiatric Disease and Treatment 14, pages 1107-1117.
Read now
Read now
Tamara Tompsett, Kate Masters & Parastou Donyai. (2018) The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment. Neuropsychiatric Disease and Treatment 14, pages 681-691.
Read now
Read now
Robin Emsley & Sanja Kilian. (2018) Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Disease and Treatment 14, pages 205-223.
Read now
Read now
Miquel Bioque & Miquel Bernardo. (2018) The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 19:14, pages 1623-1629.
Read now
Read now
Eduard Parellada, Miquel Bioque, Manuel Serrano, Berta Herrera & Marta García Dorado. (2018) An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study). International Journal of Psychiatry in Clinical Practice 22:3, pages 191-199.
Read now
Read now
Jingping Zhao, Lehua Li, Jianguo Shi, Yi Li, Xiufeng Xu, Keqing Li, Lili Zhang, Shangli Cai, Yu Feng, Jianmin Zhuo, Weihong Liu & Huafei Lu. (2017) Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. Neuropsychiatric Disease and Treatment 13, pages 2045-2056.
Read now
Read now
Tianmei Si, Jianmin Zhuo, Ibrahim Turkoz, Maju Mathews, Wilson Tan & Yu Feng. (2017) Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety. Expert Opinion on Pharmacotherapy 18:17, pages 1799-1809.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, Fadi Tedouri, Kristel Van Impe, Tom R. Denee & Pieter J. T. Dries. (2017) Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. Journal of Medical Economics 20:11, pages 1187-1199.
Read now
Read now
M. C. Mauri, A. Reggiori, S. Paletta, C. Di Pace & A. C. Altamura. (2017) Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation. Expert Opinion on Drug Safety 16:3, pages 365-379.
Read now
Read now
LiLi Zhang, JiTao Li, YanJie Zhao, Yun’Ai Su & Tianmei Si. (2016) Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatric Disease and Treatment 12, pages 113-131.
Read now
Read now
Bernardo Carpiniello & Federica Pinna. (2016) Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia. Drug Design, Development and Therapy 10, pages 1731-1742.
Read now
Read now
Miquel Bernardo & Miquel Bioque. (2016) Three-month paliperidone palmitate - a new treatment option for schizophrenia. Expert Review of Clinical Pharmacology 9:7, pages 899-904.
Read now
Read now
Alexandre González-Rodríguez, Rosa Catalán, Rafael Penadés, Clemente Garcia-Rizo, Miquel Bioque, Eduard Parellada & Miquel Bernardo. (2015) Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review. Patient Preference and Adherence 9, pages 695-706.
Read now
Read now
Chiun-Fang Chiou, Bruce CM Wang, Ronald Caldwell, Wesley Furnback, Jung-Sun Lee, Nathan Kothandaraman, Sun Kyoung Lee, Jin Wang & Fan Zhang. (2015) The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia. Neuropsychiatric Disease and Treatment 11, pages 1989-1994.
Read now
Read now
Articles from other publishers (19)
Gülay TAŞCI & Filiz ÖZSOY. (2022) Depo antipsikotik kullanan hastalarda prolaktin düzeyi, cinsel fonksiyon, vücut kitle indeksi ve karaciğer fonksiyon testlerinin karşılaştırılmasıComparison of prolactin level, sexual function, body mass index, and liver function tests in patients using depot antipsychotics. Cukurova Medical Journal 47:3, pages 1172-1178.
Crossref
Crossref
Lulu Lian, David D. Kim, Ric M. Procyshyn, Diana Cázares, William G. Honer & Alasdair M. Barr. (2022) Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. PLOS ONE 17:4, pages e0267808.
Crossref
Crossref
Christoph U. Correll, Amber Martin, Charmi Patel, Carmela Benson, Rebecca Goulding, Jennifer Kern-Sliwa, Kruti Joshi, Emma Schiller & Edward Kim. (2022) Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia 8:1.
Crossref
Crossref
Wonsuk Shin, Dong Hyeon Lee, Min‐Kyoung Kim, Sang‐Hyuk Lee, Doo‐Yeoun Cho & Minji Bang. (2021) Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: A retrospective real‐world study in South Korea. Early Intervention in Psychiatry 15:6, pages 1759-1767.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Crossref
Massimo Carlo Mauri, Alessandra Reggiori, Alessandro Minutillo, Gemma Franco, Chiara Di Pace, Silvia Paletta & Dario Cattaneo. (2020) Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the
Prophylaxis of Bipolar Disorder Type I with Manic Predominance. Pharmacopsychiatry 53:05, pages 209-219.
Crossref
Crossref
Dasom Lee, Boung Chul Lee, Soo-Hee Choi, Do-Hyung Kang, Duk-In Jon & Myung Hun Jung. (2020) Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea. Clinical Psychopharmacology and Neuroscience 18:2, pages 303-310.
Crossref
Crossref
J. Potaufeu, B. Langrée, D. Drapier, G. Burgot & N. Marie. (2019) Étude coût-efficacité du pamoate d’olanzapine : analyse en miroir sur un an. L'Encéphale 45:3, pages 232-238.
Crossref
Crossref
Tze-Chun Tang, Ming-Hong Hsieh, Chen-Chung Liu, Nan-Ying Chiu, Fong-Lin Jang, Chih-Lin Chiang & Tung-Ping Su. (2019) Long-term safety, efficacy, treatment satisfaction, and impact on healthcare service use of paliperidone palmitate one-month intramuscular formulation in patients with recent-onset schizophrenia in taiwan: A subgroup analysis of an asia-pacific, 18-month, phase 3b study. Taiwanese Journal of Psychiatry 33:4, pages 198.
Crossref
Crossref
Richard Newton, Alice Rouleau, Anna-Greta Nylander, Jean-Yves Loze, Henrike K. Resemann, Sara Steeves & Benedicto Crespo-Facorro. (2018) Diverse definitions of the early course of schizophrenia—a targeted literature review. npj Schizophrenia 4:1.
Crossref
Crossref
Tianmei Si, Nan Li, Huafei Lu, Shangli Cai, Jianmin Zhuo, Christoph U Correll, Lili Zhang & Yu Feng. (2018) Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. Journal of Psychopharmacology 32:6, pages 691-701.
Crossref
Crossref
Robin Emsley, Eduard Parellada, Miquel Bioque, Berta Herrera, Teresa Hernando & Marta García-Dorado. (2018) Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders. International Clinical Psychopharmacology 33:1, pages 15-33.
Crossref
Crossref
Hongyan Zhang, Ibrahim Turkoz, Jianmin Zhuo, Maju Mathews, Wilson Tan & Yu Feng. (2017) Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia. Advances in Therapy 34:11, pages 2503-2517.
Crossref
Crossref
. (2016) Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies. Drugs & Therapy Perspectives 33:1, pages 28-31.
Crossref
Crossref
Edward Kim, Christoph U. Correll, Lian Mao, H. Lynn Starr & Larry Alphs. (2016) Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS Spectrums 21:6, pages 466-477.
Crossref
Crossref
F. Pietrini, M. Spadafora, L. Tatini, G.A. Talamba, C. Andrisano, G. Boncompagni, M. Manetti, V. Ricca & A. Ballerini. (2020) LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment. European Psychiatry 37, pages 35-42.
Crossref
Crossref
Eduard Parellada & Miquel Bioque. (2016) Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. CNS Drugs 30:8, pages 689-701.
Crossref
Crossref
Eraldo Francesco Nicotra, Gianluca Casu, Sara Piras, Mario Palomba & Giorgio Marchese. (2016) On the positive and negative syndrome scale and remission in schizophrenia. On the positive and negative syndrome scale and remission in schizophrenia.
P. Chue & J. Chue. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
35
54
.